GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...] …
Month: August 2023
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...] …
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...] …
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...] …
Drug makers AbbVie, Bristol Myers Squibb, Janssen, Lilly, and Merck asked a federal district court in South Carolina on Friday [...] …
Changes in the ways Medicare calculates hospitals’ shares of low-income patients that were finalized in a recent payment rule will [...] …
SPONSORED CONTENT
Are you telling your 340B story? This webinar will teach you how to track the key data points that demonstrate the value of your 340B program. You will learn how to calculate your overall savings, track patient benefits, and create an Impact Profile.
…
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] …
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...] …
Drug manufacturer Merck recently loosened its 340B program contract pharmacy restrictions in Louisiana and Arkansas just before Louisiana’s law protecting [...] …